Lidokain Aguettant

Lidocaine, the active ingredient in Lidokain Aguettant, is a local anesthetic presented as a sterile solution for infiltration and intravenous use. It provides reversible nerve blockade for minor surgical procedures, regional anesthesia and acute pain management in adult patients. GNH USA supplies Lidokain Aguettant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lidokain Aguettant is a local anesthetic used in procedures that require temporary loss of sensation. - Minor surgical procedures: provides localized numbness to facilitate incision and suturing. - Regional anesthesia: enables nerve block for limb or trunk surgeries, reducing the need for general anesthesia. - Pain management: offers short‑term relief of acute procedural or postoperative pain.

Lidokain Aguettant may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Localized burning or tingling at the injection site. - Mild swelling or erythema around the administered area. - Transient dizziness or light‑headedness.

Serious or Rare Side Effects: - Systemic toxicity presenting as seizures, cardiac arrhythmia, or hypotension. - Allergic reactions such as urticaria, angioedema, or anaphylaxis. - Methemoglobinemia, a rare blood disorder causing reduced oxygen delivery.

Before using Lidokain Aguettant, consider the following safety measures. - Allergy assessment: verify no known hypersensitivity to amide‑type local anesthetics. - Cardiovascular status: avoid in patients with severe heart block or conduction disorders. - Dosage limits: adhere to recommended maximum dose to prevent systemic toxicity. - Concurrent CNS depressants: use with caution as they may enhance neurotoxic effects. - Pregnancy and lactation: assess risk–benefit before use. - Store at ambient temperature: keep in original container, protect from light and moisture.

Lidokain Aguettant can interact with several drug classes; monitoring is essential.

Major Interactions (Avoid): - Class I antiarrhythmic agents (e.g., quinidine, procainamide): may increase plasma lidocaine levels. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can raise systemic exposure. - Beta‑adrenergic blockers: may potentiate cardiac depressant effects.

Moderate Interactions (Monitor Closely): - Other local anesthetics: additive toxicity risk when combined. - General anesthetics (e.g., propofol, volatile agents): may enhance central nervous system depression. - Diuretics (e.g., furosemide): may alter plasma protein binding and affect lidocaine clearance.